

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. _____)*

SpectRx, Inc.

(Name of Issuer)

Common stock par value \$.001 per share

(Title of Class of Securities)

847 635 109

(CUSIP Number)

Jose M. de Lasa, 100 Abbott Park Road
Abbott Park, Illinois 60064-3500; Phone (847) 937-8905

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

July 7, 1997

(Date of Event which Requires
Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.

Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.)

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

(Continued on following page(s))

1 | NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 Abbott Laboratories
 IRS Identification Number: 36-0698440

2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / /
 (b) /x/

3 | SEC USE ONLY

4 | SOURCE OF FUNDS*
 WC

5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
 ITEMS 2(d) or 2(e) / /

6 | CITIZENSHIP OR PLACE OF ORGANIZATION
 Illinois

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 500,143
	8	SHARED VOTING POWER
	9	SOLE DISPOSITIVE POWER 500,143
	10	SHARED DISPOSITIVE POWER

11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 500,143

12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
 SHARES* / /

13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 6.61%

14 | TYPE OF REPORTING PERSON*
 CO

* SEE INSTRUCTIONS BEFORE FILLING OUT!

ITEM 1. SECURITY AND ISSUER

This statement relates to shares of the common stock, par value \$.001 per share (the "Common Stock"), of SpectRx, Inc., a Delaware corporation (the "Issuer"), whose principal executive offices are located at 6025A, Unity Drive, Norcross, Georgia, 30071.

ITEM 2. IDENTITY AND BACKGROUND

(a) - (c), and (f) The person filing this statement is Abbott Laboratories ("Abbott"), an Illinois corporation. Abbott's principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products and services. Abbott's principal office is located at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500.

The names, citizenship, business addresses, present principal occupation or employment and the name, and the principal business and address of any corporation or other organization in which such employment is conducted of the directors and executive officers of Abbott are as set forth in Exhibit 1 hereto and incorporated herein by this reference.

(d) and (e) Neither Abbott, nor to the best of its knowledge, any person listed on Exhibit 1 has during the last five years (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

On July 7, 1997, Abbott purchased 143,000 shares of Common Stock and paid \$1,001,000 for these 143,000 shares. These funds came from Abbott's general assets.

ITEM 4. PURPOSE OF THE ACQUISITION

Abbott acquired the shares of Common Stock as an investment.

(a) - (j) At present, Abbott does not have any plans or proposals which would relate to or result in transactions of the kind described in paragraphs (a) through (j) of Item 4 of Schedule 13D of the Securities and Exchange Commission. Abbott does, however, reserve the right to adopt such plans or proposals subject to compliance with applicable regulatory requirements.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

(a) Abbott is the beneficial owner of 500,143 shares of Common Stock. This represents approximately six and 61/100 percent (6.61%) of the outstanding shares of the Common Stock. The calculation of the foregoing percentage is based on the number of shares of Common Stock shown as being outstanding in the Issuer's prospectus dated July 1, 1997.

(b) Abbott has sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the Shares.

(c) Except as described herein, there have been no transactions by Abbott or the persons whose names are listed on Exhibit 1 in securities of the Issuer during the past sixty days.

(d) No one other than Abbott is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from a sale of the Shares.

(e) Not applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

None

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

Exhibit 1 - Information Concerning Executive Officers and
Directors of Abbott Laboratories.

After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.

Abbott Laboratories

DATED: July 14, 1997

By: /s/ Gary P. Coughlan

Gary P. Coughlan, Senior Vice President,
Finance and Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NUMBER	DESCRIPTION	SEQUENTIAL PAGE NUMBER
1	Information Concerning Executive Officers and Directors of Abbott Laboratories.	

Exhibit 1

Information Concerning Executive Officers and
Directors of Abbott Laboratories

The current corporate officers and directors of Abbott Laboratories are listed below. The address of Abbott Laboratories is: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-3500. Abbott Laboratories does not consider all of its corporate officers to be executive officers as defined by the Securities Exchange Act of 1934 or Releases thereunder. Unless otherwise indicated, all positions set forth below opposite an individual's name refer to positions within Abbott Laboratories, and the business address listed for each individual not principally employed by Abbott Laboratories is also the address of the corporation or other organization which principally employs that individual.

NAME	POSITION/PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND BUSINESS ADDRESS	CITIZENSHIP
CORPORATE OFFICERS		
Duane L. Burnham(1)	Chairman of the Board and Chief Executive Officer	U. S. A.
Thomas R. Hodgson(1)	President and Chief Operating Officer	U. S. A.
Joy A. Amundson(1)	Senior Vice President, Chemical and Agricultural Products	U. S. A.
Paul N. Clark(1)	Senior Vice President, Pharmaceutical Operations	U. S. A.
Gary P. Coughlan(1)	Senior Vice President, Finance and Chief Financial Officer	U. S. A.
Jose M. de Lasa(1)	Senior Vice President, Secretary and General Counsel	U. S. A.
John G. Kringel(1)	Senior Vice President, Hospital Products	U. S. A.
Thomas M. McNally(1)	Senior Vice President, Ross Products	U. S. A.
Robert L. Parkinson, Jr.(1)	Senior Vice President, International Operations	U. S. A.
Ellen M. Walvoord(1)	Senior Vice President, Human Resources	U. S. A.
Miles D. White(1)	Senior Vice President, Diagnostic Operations	U. S. A.

Exhibit 1

Information Concerning Executive Officers and
Directors of Abbott Laboratories

NAME	POSITION/PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND BUSINESS ADDRESS	CITIZENSHIP
CORPORATE OFFICERS - Continued		
Catherine V. Babington(1)	Vice President, Investor Relations and Public Affairs	U. S. A.
Patrick J. Balthrop	Vice President, Diagnostic Operations, U.S. and Canada	U. S. A.
Mark E. Barmak	Vice President, Litigation and Government Affairs	U. S. A.
Christopher B. Begley	Vice President, MediSense	U. S. A.
Thomas D. Brown	Vice President, Diagnostic Commercial Operations	U. S. A.
Gary R. Byers(1)	Vice President, Internal Audit	U. S. A.
William G. Dempsey	Vice President, Hospital Products Business Sector	U. S. A.
Kenneth W. Farmer(1)	Vice President, Management Information Services and Administration	U. S. A.
Thomas C. Freyman(1)	Vice President and Treasurer	U. S. A.
David B. Goffredo	Vice President, Pharmaceutical Products Marketing and Sales	U. S. A.
Rick A. Gonzalez(1)	Vice President, HealthSystems	U. S. A.

Exhibit 1

Information Concerning Executive Officers and
Directors of Abbott Laboratories

NAME	POSITION/PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND BUSINESS ADDRESS	CITIZENSHIP
CORPORATE OFFICERS - Continued		
Guillermo A. Herrera	Vice President, Latin America Operations	Columbia
Arthur J. Higgins	Vice President, Pacific, Asia, and Africa Operations	United Kingdom
Jay B. Johnston	Vice President, Diagnostic Assays and Operations	U. S. A.
James J. Koziarz, Ph.D.	Vice President, Diagnostic Products Research and Development	U. S. A.
John F. Lussen(1)	Vice President, Taxes	U. S. A.
Edward L. Michael	Vice President, Diagnostic Operations, Europe, Africa, and Middle East	U. S. A.
Theodore A. Olson(1)	Vice President and Controller	U. S. A.
Andre G. Pernet, Ph.D.	Vice President, Pharmaceutical Products Research and Development	U. S. A.
Carl A. Spalding	Vice President, Ross Pediatric Products	U. S. A.
William H. Stadlander	Vice President, Ross Medical Nutritional Products	U. S. A.
Marcia A. Thomas(1)	Vice President, Corporate Quality Assurance and Regulatory Affairs	U. S. A.
H. Thomas Watkins	Vice President, Diagnostic Operations, Asia and Pacific	U. S. A.
Steven J. Weger(1)	Vice President, Corporate Planning and Development	U. S. A.
Josef Wendler	Vice President, European Operations	Germany
Lance B. Wyatt(1)	Vice President, Corporate Engineering	U. S. A.

Exhibit 1

Information Concerning Executive Officers and
Directors of Abbott Laboratories

NAME	POSITION/PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND BUSINESS ADDRESS	CITIZENSHIP
DIRECTORS		
K. Frank Austen, M.D.	Professor of Medicine, Harvard Medical School The Seeley G. Mudd Building, Room 604 250 Longwood Avenue Boston, Massachusetts 02115	U. S. A.
Duane L. Burnham	Officer of Abbott	U. S. A.
H. Laurance Fuller	Chairman, President, and Chief Executive Officer Amoco Corporation 200 East Randolph Drive Mail Code 3000 Chicago, Illinois 60601 (integrated petroleum and chemicals company)	U. S. A.
Thomas R. Hodgson	Officer of Abbott	U. S. A.
David A. Jones	Chairman and Chief Executive Officer Humana Inc. 500 W. Main St. Humana Building Louisville, Kentucky 40201 (Health Plan Business)	U. S. A.
The Rt. Hon. the Lord Owen CH	British Member of Parliament 20 Queen Anne's Gate Westminster, London SW1H 9AA, England	United Kingdom

Exhibit 1

Information Concerning Executive Officers and
Directors of Abbott Laboratories

NAME	POSITION/PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND BUSINESS ADDRESS	CITIZENSHIP
----- DIRECTORS - CONTINUED		
Boone Powell, Jr.	President and Chief Executive Officer Baylor Health Care System and Baylor University Medical Center, Vice President, Baylor University 3500 Gaston Avenue Dallas, Texas 75246	U. S. A.
Addison Barry Rand	Executive Vice President Xerox Corporation 800 Long Ridge Road Stamford, Connecticut 06904-1600 (document processing, insurance and financial services company)	U. S. A.
Dr. W. Ann Reynolds	Chancellor The City University of New York 535 E. 80th Street New York, New York 10021	U. S. A.
William D. Smithburg	Chairman, President and Chief Executive Officer The Quaker Oats Company 321 N. Clark Street Chicago, Illinois 60610 (worldwide food manufacturer and marketer of beverages and grain-based products)	U. S. A.
John R. Walter	President and Chief Operating Officer AT&T Corporation 295 North Maple Avenue Room 4353L1 Basking Ridge, New Jersey 07920 (telecommunications company)	U. S. A.

Exhibit 1

Information Concerning Executive Officers and
Directors of Abbott Laboratories

NAME	POSITION/PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND BUSINESS ADDRESS	CITIZENSHIP
DIRECTORS - CONTINUED		
William L. Weiss	Chairman Emeritus, Ameritech Corporation One First National Plaza Suite 2530C Chicago, Illinois 60603-2006 (telecommunications company)	U. S. A.

1 Pursuant to Item 401(b) of Regulation S-K Abbott has identified these persons as "executive officers" within the meaning of Item 401(b).